MOv18 IgE is the first‐in‐class anti‐cancer IgE, recognising the human TAA, folate receptor alpha (FRα) [2], a glycosylphosphatidylinositol‐anchored membrane folate receptor that supports tumour growth [6]. Here, IGHE is linked to cancer.